NEW YORK (TheStreet) -- TheStreet's Jim Cramer answers Twitter (TWTR - Get Report) questions from the floor of the New York Stock Exchange, and this week's first question deals with Tesla (TSLA - Get Report), which received an upgrade from Deutsche (DB - Get Report) on Monday.
Cramer says investors must stay long on Tesla. If Deutsche is right, which Cramer thinks they are, then the scale and profit here are much bigger than he thought. Cramer believes Deutsche's upgrade to "buy" with a $310 price target will move the stock substantially, so he would not sell it.
The next question asks for Cramer's pharma plays given the ongoing Ebola issue, and he notes investors have driven up Tekmira Pharmaceuticals (TKMR - Get Report), a smaller company. He thinks people keep shorting it and expecting it to go down, but says the stock will obviously soar if the company has an Ebola cure. Cramer thinks the trade has been done and would take profits on the stock.
"We rate SOLARCITY CORP (SCTY) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its poor profit margins, weak operating cash flow, generally high debt management risk and feeble growth in its earnings per share." You can view the full analysis from the report here: SCTY Ratings Report EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.